Product Description: Conessine is an orally active and BBB-penetrable selective histamine H3 receptor antagonist. The pKi values of Conessine for rat and human H3 receptors are 7.61 and 8.27, respectively. Conessine is an inhibitor of the multidrug efflux pump system in Pseudomonas aeruginosa and can enhance the activity of antibiotics. Conessine has antimalarial activity. Conessine can also be used in the research of muscle atrophy[1][2][3][4][5].
Applications: COVID-19-immunoregulation
Formula: C24H40N2
References: [1]Kim H, et al. Conessine treatment reduces dexamethasone-induced muscle atrophy by regulating MuRF1 and atrogin-1 expression [published online ahead of print, 2018 Feb 1]. J Microbiol Biotechnol. 2018;10.4014.jmb.1711.11009./[2]Siriyong T, et al. Conessine as a novel inhibitor of multidrug efflux pump systems in Pseudomonas aeruginosa. BMC Complement Altern Med. 2017 Aug 14;17(1):405./[3]Dua VK, et al. Anti-malarial property of steroidal alkaloid conessine isolated from the bark of Holarrhena antidysenterica. Malar J. 2013 Jun 10;12:194./[4]Morais-Silva G, et al. Conessine, an H3 receptor antagonist, alters behavioral and neurochemical effects of ethanol in mice. Behav Brain Res. 2016 May 15;305:100-7./[5]Zhao C, et al. The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. J Med Chem. 2008 Sep 11;51(17):5423-30.
CAS Number: 546-06-5
Molecular Weight: 356.59
Compound Purity: 99.87
Research Area: Infection; Neurological Disease
Solubility: DMSO : 3.33 mg/mL (ultrasonic;warming;heat to 60°C)/Ethanol : 25 mg/mL (ultrasonic)
Target: Bacterial;FOXO;Histamine Receptor;MDM-2/p53;NF-κB;Parasite
English
Deutsch
